+

WO2000061201A1 - Procedes visant a inhiber des infections microbiennes associees a des produits hygieniques - Google Patents

Procedes visant a inhiber des infections microbiennes associees a des produits hygieniques Download PDF

Info

Publication number
WO2000061201A1
WO2000061201A1 PCT/US2000/010222 US0010222W WO0061201A1 WO 2000061201 A1 WO2000061201 A1 WO 2000061201A1 US 0010222 W US0010222 W US 0010222W WO 0061201 A1 WO0061201 A1 WO 0061201A1
Authority
WO
WIPO (PCT)
Prior art keywords
lactobacillus
composition
absorbent
product
bacteria
Prior art date
Application number
PCT/US2000/010222
Other languages
English (en)
Inventor
Sean Farmer
Andrew R. Lefkowitz
Original Assignee
Ganeden Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/291,789 external-priority patent/US6716435B1/en
Application filed by Ganeden Biotech, Inc. filed Critical Ganeden Biotech, Inc.
Priority to CA002368509A priority Critical patent/CA2368509A1/fr
Priority to JP2000610532A priority patent/JP2002540900A/ja
Priority to EP00923406A priority patent/EP1173233A1/fr
Priority to AU43533/00A priority patent/AU780367B2/en
Publication of WO2000061201A1 publication Critical patent/WO2000061201A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/36—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing microorganisms

Definitions

  • the claimed invention relates to systems and methods to inhibit microbial infections and to promote epithelial probiosis when using sanitary health care products such as disposable diapers and other sanitary products.
  • sanitary health care products such as disposable diapers and other sanitary products.
  • the claimed invention describes use of probiotic lactic acid bacteria in combination with sanitary health care products to inhibit microbial infections, promote dermal probiosis, and enhance biodegradatability of disposed sanitary products.
  • Sanitary products are widely used in various formats for personal hygiene and medical necessity, and include sanitary napkins, diapers, incontinence guards, wound dressings and the like. By their use, a local tissue environment is produced which promotes growth of microbial pathogens, local infections, irritation, rashes, and related problems.
  • the claimed invention uses a bacterium that is probiotic and heterotrophic to resolve both of the above problems (i.e., to inhibit microbial infections associated with use of sanitary products, and to promote biodegradation of the sanitary product after use).
  • Probiotic microorganisms are those which confer a benefit when grow in a particular environment, often by inhibiting the growth of other biological organisms in the same environment.
  • Examples of probiotic organisms include bacteria and bacteriophages which possess the ability to grow within the gastrointestinal tract, at least temporarily, to displace or destroy pathogenic organisms, as well as providing other benefits to the host. See e.g., Salminen et al, 1996. Antonie Van Leeuwenhoek 70: 347-358; Elmer et al, 1996.
  • probiotics are members of the normal colonic micro-flora and are not viewed as being overtly pathogenic. However, these organisms have occasionally caused infections (e.g., bacteremia) in individuals who are, for example, immunocompromised. See e.g., Sussman, J. et al, 1986. Rev Infect. Dis. 8: 771-776; Hata, D. et al, 1988. Pediatr. Infect. Dis. 7: 669-671.
  • probiotic bacteria found in sour milk has been utilized since ancient times (i.e., long-before the discovery of bacteria) as a therapeutic treatment for dysentery and related gastrointestinal diseases. More recently, probiotic preparations were systematically evaluated for their effect on health and longevity in the early- 1900's (see e.g., Metchinikoff, E., Prolongation of Life, Willaim Heinermann, London 1910), although their utilization has been markedly limited since the advent of antibiotics in the 1950's to treat pathological microbes. See e.g., Winberg, et al, 1993. Pediatr. Nephrol 7: 509-514; Malin et al, Ann. Nutr. Metab.
  • lactic acid-producing bacteria e.g., Bacillus, Lactobacillus and Streptococcus species
  • Lactobacillus and Biffidobacterium strains that colonize the gut has been previously disclosed (Winberg, et al, Pediatr. Nephrol. 7: 509-514, 1993; Malin, et al, Ann. Nutr. Metab. 40:137-145, 1996; and U.S. Patent. No. 4,176,911).
  • Lactic acid producing bacteria e.g., Bacillus, Lactobacillus and Streptococcus species
  • Heterotrophic bacteria play an important role in the biodegradation of animal waste and many natural and synthetic polymers.
  • Bacterial strains including: Bacillus, Pseudomonas, Arthrobacter, Achromobacter, Micrococcus and Rhodococcus have been shown to participate in the breakdown of waste products, cellulose materials, petroleum hydrocarbons and their associated products, such as plastics, synthetic rubbers and other synthetic materials.
  • Bacillus coagulans is a non-pathogenic gram positive spore-forming bacteria that produces L(+) lactic acid (dextrorotatory) in homofermentation conditions. It has been isolated from natural sources, such as heat-treated soil samples inoculated into nutrient medium (Bergey's Manual off Systemic Bacteriology, Vol. 2, Sneath, P.H.A., et al, eds., Williams & Wilkins, Baltimore, MD, 1986). Purified R. coagulans strains have served as a source of enzymes including endonucleases (e.g., U.S. Patent No. 5,200,336); amylase (U.S. Patent No. 4,980,180); lactase (U.S. Patent No. 4,323,651); and cyclo-malto-dextrin glucano-transferase
  • endonucleases e.g., U.S. Patent No. 5,200,336
  • R. coagulans has been used to produce lactic acid (U.S. Patent No. 5,079,164).
  • a strain of R. coagulans (referred to as L. sporogenes; Sakaguti & Nakayama (ATCC 31284)) has been combined with other lactic acid producing bacteria and R. natto to produce a fermented food product from steamed soybeans (U.S. Patent No. 4,110,477).
  • Use of a sanitary product produces frequent dermal mucoidal irritations and/or infections associated with the use of the product. Diaper rash is a common issue in both adults and infants.
  • vulva- vaginal infections are common with the use of napkins and tampons and are typically caused by Candida or Gardnerella species (e.g., Candida albicans and C. tropicalis). Toxic Shock
  • Staphylococcal bacteria e.g., Staphylococcus aureus and S. epidermidis
  • Other pathogens which can cause infection after brief periods of dermal irritation and/or use of sanitary products include Trichophyton species (e.g., T. mentagrophytes).
  • Trichophyton species e.g., T. mentagrophytes
  • disposable diapers and other sanitary products present environmental problems in their disposal. Sanitary landfills are overused and accumulate excessive amounts of disposed products. Sanitary products such as diapers, sanitary napkins and tampons biodegrade slowly and occupy considerable space due to the bulk of these products, particularly when containing body excrements or fluids which expand due to their absorbent polymer content.
  • probiotic acid-producing bacteria are effective in inhibiting, preventing and/or eliminating dermal/epithelial infections by preventing the growth of dermal pathogens which grow upon use of diapers and other sanitary products. It has also been discovered that bacterial enzymes and other metabolic products of probiotic acid-producing bacteria play an important role in the biodegradation of many sanitary products, including biodegradation of the waste biomaterials, such as when disposed in landfills.
  • the claimed invention discloses compositions and articles of manufacture containing non-pathogenic probiotic acid-producing bacteria, and their methods of use for inhibiting pathogen growth on skin in applications where sanitary products are used, which also provides for degradation of the sanitary products and body waste products contained thereby.
  • the invention contemplates sanitary products as articles of manufacture which contain effective amounts of a probiotic bacterium in various parts of the product so as to achieve the desired result of inhibiting microbial infections on the tissues in contact with the sanitary product and/or enhance biodegradation of the sanitary product and waste products collected upon the sanitary product.
  • the probiotic acid-producing bacteria is introduced into or onto portions of the sanitary product by applying a composition containing viable bacteria to the product during a stage of the manufacture of the sanitary product.
  • the invention contemplates using a lactic acid-producing bacteria, and more preferably using spore-forming Bacillus species, particularly R. coagulans, being a preferred embodiment, and R. coagulans Hammer being a particularly preferred embodiment.
  • a Bacillus coagulans strain is included in the composition in the form of spores.
  • a Bacillus coagulans strain is included in the composition in the form of a dried cell mass.
  • a Bacillus coagulans strain is included in the composition in the form of a stabilized paste.
  • a Bacillus coagulans strain is included in the composition in the form of stabilized gel.
  • the composition further includes an effective amount of a bifidogenic oligosaccharide, such as a short or long chain fhictooligosaccharide (FOS), a gluco-oligosaccharide or other long-chain oligosaccharide polymer not readily digested by pathogenic bacteria as described herein.
  • a bifidogenic oligosaccharide such as a short or long chain fhictooligosaccharide (FOS)
  • FOS long chain fhictooligosaccharide
  • lactic acid bacteria such as the exemplary Bacillus coagulans
  • lactic acid bacteria can be used in compositions as a probiotic for inhibiting growth of microbial dermal and epithelial pathogens which can occur upon use of various sanitary products.
  • these bacteria can be used as a preventative or ameliorative treatment of rashes and other dermal infections that manifest themselves as a result of use of the sanitary product, including irritated/inflamed skin, dermatitis, excema, or skin allergies.
  • the invention describes the use of one or more bacteria species to enhance degradation of the sanitary product, which are included in the compositions, methods and articles of manufacture of this invention and are referred to herein as "degradative bacteria”.
  • a sanitary product can be any of variety of materials used in contact with a body tissue which, upon use, is susceptible to dermal or epithelial rashes and/or infections.
  • Exemplary sanitary products include an infant or adult diaper, sanitary napkin, tampon, incontinence guard, bed sheet or protector, wound or sore dressing, dermal patch, adhesive tape, saliva absorbent, and related disposable sanitary and hygiene products, although the invention need not be viewed as so limited.
  • the composition further comprises an effective amount of a bifidogenic oligosaccharide, such as fructo-oligosaccharide (FOS), gluco-oligosaccharide (GOS) and the like, as described herein.
  • a bifidogenic oligosaccharide such as fructo-oligosaccharide (FOS), gluco-oligosaccharide (GOS) and the like, as described herein.
  • a probiotic acid-producing bacteria suitable for use in the methods and compositions of the invention as defined for use in the present invention produces acid and is non-pathogenic.
  • suitable bacteria identified as described herein, although the invention is not limited to currently known bacterial species insofar as the purposes and objectives of the bacteria is described.
  • the property of acid production is key to the effectiveness of the probiotic lactic acid-producing bacteria of this invention because the lactic acid production increases acidity in the local micro floral environment, which does not support growth of many deleterious and undesirable bacteria and fungi. By the mechanism of lactic acid production, the probiotic inhibits growth of competing and deleterious bacteria.
  • probiotic refers to microorganisms that form at least a part of the transient or endogenous flora and thereby exhibit a beneficial prophylactic and/or therapeutic effect on the host organism.
  • Probiotics are generally known to be safe by those skilled in the art (i.e., non-pathogenic).
  • the prophylactic and/or therapeutic effect of an lactic acid-producing bacteria of this invention results in part from competitive inhibition of growth of pathogens due to superior colonization, parasitism of undesirable microorganisms, lactic acid production and/or other extracellular products having antimicrobial activity, or combinations thereof.
  • These products and activities of an lactic acid-producing bacteria of this invention act synergistically to produce the beneficial probiotic effect.
  • Typical lactic acid-producing bacteria i.e., a " lactic acid bacteria" useful as a probiotic of this invention are efficient acid producers which include non-pathogenic members of the
  • Bacillus genus all members of the Lactobacillus and Sporolactobacillus genus, all members of the Bifidobacterium genus, and Pseudomonas limbergii, although certain species are particularly preferred as described herein.
  • Preferred lactic acid-producing bacteria include the Bacillus laterosporus or Bacillus subtilis species described herein, including Bacillus laterosporus, Bacillus laterosporus BOD, Bacillus laterosporus laubach and Bacillus subtilis.
  • the present invention contemplates the use of a lactic acid-producing bacteria ("lactic acid bacteria") which includes the above Lactobacillus, Bifidobacterium and certain Bacillus species.
  • lactic acid-producing bacteria such as L. sporogenes (aka R. coagulans), Sporolactobacillus P44, and Bacillus brevis subsp. coagulans.
  • Exemplary lactic acid-producing, non-pathogenic Bacillus species are Bacillus coagulans, Bacillus coagulans Hammer, Bacillus brevis subspecies coagulans and Bacillus laevolacticus.
  • Exemplary lactic acid-producing Lactobacillus species include Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus cereale, Lactobacillus DDS-I, Lactobacillus delbrukeii, Lactobacillus fermentum, Lactobacillus gaserii, Lactobacillus GG, Lactobacillus jensenii, Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus salivarius, Lactobacillus sporogenes (aka R. coagulans) and Lactobacillus thermophilus.
  • Exemplary lactic acid-producing Sporolactobacillus species include all Sporolactobacillus species, including Sporolactobacillus P44.
  • Exemplary lactic acid-producing Bifidobacterium species include: Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium bifidus, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium infantus and Bifidobacterium longum.
  • Bacillus species particularly useful as a probiotic according to the present invention including the lactic acid-producers Bacillus coagulans, and Bacillus laevolacticus.
  • Bacillus coagulans is only a model for the other lactic acid producing species of probiotic bacteria useful in the practice of the present invention, and therefore the invention is not to be considered as limiting and it is intended that any of the acid producing species of probiotic bacteria can be used in the compositions, therapeutic systems and methods of the present invention.
  • Bacillus species useful in the present invention including, but not limited to many different strains available through commercial and public sources, such as the -American Type Culture Collection (ATCC).
  • ATCC American Type Culture Collection
  • Bacillus coagulans strains are available as ATCC Accession Numbers 15949, 8038, 35670, 11369, 23498, 51232, 11014, 31284, 12245, 10545 and 7050.
  • Bacillus laevolacticus strains are available as ATCC Accession Numbers 23495, 23493, 23494, 23549 and 23492.
  • a Bacillus species is particularly suited for the present invention, particularly species having the ability to form spores which are relatively resistant to heat and other conditions, making them ideal for storage (shelf- life) in product formulations, and ideal for survival and colonization of tissues under conditions of pH, salinity, and the like on tissues of the skin and epithelium. Additional useful properties include being non-pathogenic, aerobic, facultative and heterotrophic, rendering these species safe, and able to colonize skin and epithelium.
  • Bacillus spores are heat-resistant and additionally can be stored as a dry power, they are particularly useful for formulation into and manufacture of dry products such as the various sanitary products and compositions described herein. Heat and pressure-resistant spores are also suitable for use in pressure-treated absorbent compositions described herein. Exemplary methods and compositions are described herein using Bacillus coagulans as a probiotic. Purified Bacillus coagulans is particularly useful as a probiotic in the present invention. Probiotic R. coagulans is non-pathogenic and is generally regarded as safe (i.e., GRAS classification) by the U.S. Federal Drug Administration (FDA) and the U.S. Department of Agriculture (USD A), and by those skilled in the art. The Gram positive rods of B.
  • FDA U.S. Federal Drug Administration
  • USD A U.S. Department of Agriculture
  • coagulans have a cell diameter of greater than 1.0 micrometer ( m ) with variable swelling of the sporangium, without parasporal crystal production. Because R. coagulans forms heat-resistant spores, it is particularly useful for making pharmaceutical compositions that require heat and pressure in their manufacture. Formulations that include viable R. coagulans spores in a pharmaceutically acceptable carrier are particularly preferred for making and using compositions according to the present invention.
  • the growth of these various Bacillus species to form cell cultures, cell pastes and spore preparations is generally well known in the art. Exemplary culture and preparative methods are described herein for Bacillus coagulans and can readily be used and/or modified for growth of the other lactic acid producing bacteria of this invention.
  • Bacillus coagulans utilized in the present invention are available from the American Type Culture Collection (ATCC, Rockville, MD) using the following accession numbers: Bacillus coagulans Hammer NRS 727 (ATCC No. 11014); Bacillus coagulans Hammer strain C (ATCC No. 11369); Bacillus coagulans Hammer (ATCC No. 31284); and Bacillus coagulans Hammer NCA 4259 (ATCC No. 15949).
  • Purified Bacillus coagulans bacteria are also available from the Deutsche Sarumlung von Mikroorganismen und Zellkuturen GmbH (Braunschweig, Germany) using the following accession numbers: Bacillus coagulans Hammer 1915 (DSM No.
  • Bacillus coagulans Hammer 1915 (DSM No. 2383, corresponds to ATCC No. 11014); Bacillus coagulans Hammer (DSM No. 2384, corresponds to ATCC No. 11369); and Bacillus coagulans Hammer (DSM No. 2385, corresponds to ATCC No. 15949).
  • Bacillus coagulans bacteria can also be obtained from commercial suppliers such as Sabinsa Corporation (Piscataway, NJ) or K.K. Fermentation (Kyoto, Japan).
  • Bacillus coagulans strains and their growth requirements have been described previously (see e.g., Baker, D. et al, 1960. Can. J. Microbiol. 6: 557-563; Nakamura, H. et al, 1988. Int. J. Svst. Bacteriol 38: 63-73.
  • various strains of Bacillus coagulans can also be isolated from natural sources (e.g., heat-treated soil samples) using well-known procedures (see e.g.,
  • Bacillus coagulans had previously been mis-characterized as a Lactobacillus in view of the fact that, as originally described, this bacterium was labeled as Lactobacillus sporogenes (Nakamura, et al, Int. J. Syst. Bacteriol. 38: 63-73, 1988).
  • initial classification was incorrect due to the fact that Bacillus coagulans produces spores and through metabolism excretes L(+)-lactic acid, both aspects which provide key features to its utility. Instead, these developmental and metabolic aspects required that the bacterium be classified as a lactic acid bacillus, and therefore it was re-designated.
  • Bacillus coagulans is aerobic and facultative, grown typically in nutrient broth, pH 5.7 to
  • Bacillus coagulans can be grown in a variety of media, although it has been found that certain growth conditions produce a culture which yields a high level of sporulation. For example, sporulation is enhanced if the culture medium includes 10 milligrams per liter of manganese sulfate, yielding a ratio of spores to vegetative cells of about 80:20.
  • certain growth conditions produce a bacterial spore which contains a spectrum of metabolic enzymes particularly suited for the present invention (i.e., production of lactic acid and enzymes for the enhanced probiotic activity and biodegradation). Although spores produced by these particular growth conditions are preferred, spores produced by any compatible growth conditions are suitable for producing a R. coagulans useful in the present invention.
  • Suitable media for growth of R. coagulans include Nutristart 701, 2DB (potato dextrose broth), TSB (tryptic soy broth) and NB (nutrient broth), all well known and available from a variety of sources.
  • Media supplements containing enzymatic digests of poultry and fish tissue, and containing food yeast are particularly preferred.
  • a preferred supplement produces a media containing at least 60% protein, and about 20% complex carbohydrates and 6% lipids.
  • Media can be obtained from a variety of commercial sources, notably DIFCO (Detroit, MI), Oxoid
  • R. coagulans Probiotic Antimicrobial Activity of Bacillus coagulans
  • One aspect of the utility of R. coagulans in the present invention is based on the ability of probiotic R. coagulans to inhibit growth of pathogenic enteric microorganisms as described in the Examples.
  • Pathogenic bacteria inhibited by R. coagulans activity include: Staphylococcus aureus, S. epidermidis, Streptococcus pyogenes, Pseudomonas aeruginosa, Escherichia coli (enterohemorragic species), Clostridium species including C. perfingens, C. difficile, C. botulinum, C. tributrycum, and C.
  • compositions containing a probiotic that inhibits these pathogens are useful in preventing or treating conditions associated with infection by these pathogens.
  • R. coagulans is exemplary, by virtue of the common properties of a lactic acid- producing bacteria, a therapeutic composition comprising an acid bacterium of this invention can be used in a method or composition of this invention.
  • R. coagulans cultures contain secreted products which have antimicrobial activity. These secreted products are useful in therapeutic compositions according to the present invention. Cell cultures are harvested as described herein, and the culture supernatants are collected, by filtration or centrifugation, or both, and the resulting supernatant contains antimicrobial activity useful in a therapeutic composition. The preparation of a R. coagulans extracellular product is described in the Examples section, infra.
  • Extracellular products of R. coagulans may be included in compositions for use in the invention.
  • an effective amount of an extracellular product can be applied to a structural component part of a sanitary product of this invention, such as a diaper, bandage, sanitary napkin, tampon and the like product.
  • the claimed invention contemplates that the bacteria used in a sanitary product, system or related method according to the present invention have the ability to support biodegradation of the product as an additional feature of the invention.
  • the product, system or method comprises a degradative bacteria as described herein.
  • a degradative bacteria can be any of the bacteria previously recited which are defined as a probiotic, lactic acid- producing bacteria herein which have the property of being a degradative bacteria, or can be a different bacteria, such that two different species of bacteria are used in practicing the claimed invention. That is, is one embodiment both a probiotic acid-producing bacteria and a degradative bacteria are included in a composition, product, system or method according to the present invention.
  • Typical bacterial are any non-pathogenic bacteria which promotes degradation of human waste products, and preferably also can degrade the absorbent materials of the sanitary product of the present invention.
  • a preferred bacteria is any non-pathogenic member of the Bacillus genus, Lactobacillus genus, Sporolactobacillus genus, Bifidobacterium genus, Pseudomonas genus, and the like bacteria.
  • Bacillus genus particularly preferred members include: Bacillus acidocaldarius, Bacillus alcalophilus, Bacillus azotoformans, Bacillus badius, Bacillus brevis, Bacillus brevis subsp.
  • Bacillus cereus Bacillus chitinosporus, Bacillus circulans, Bacillus coagulans, Bacillus dextrolacticus, Bacillus firmus, Bacillus globisporus, Bacillus hydrophilus, Bacillus laevolacticus, Bacillus laterosporus, Bacillus laterosporus BOD, Bacillus laterosporus Laubach, Bacillus lentus, Bacillus licheniformis, Bacillus macerans, Bacillus marinus, Bacillus megaterium, Bacillus modestus, Bacillus mycoides, Bacillus pantothenticus, Bacillus pumilus, Bacillus polymyxa, Bacillus smithii, Bacillus stereothermophilus, Bacillus subtilis, Bacillus thermoacidurans, Bacillus thuringiensis, Bacillus uniflagellatus, and the like.
  • Particularly preferred members of the Pseudomonas genus include Pseudomonas alcaligenes, Pseudomonas limbergii, Pseudomonas pseudoalcaligenes, and Pseudomonas 679-2.
  • Particularly preferred members of the Bifidobacterium genus include Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium bifidus, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium infantus, Bifidobacterium longum, and the like.
  • Lactobacillus genus particularly preferred members include Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus cereale, Lactobacillus delbrukeii, Lactobacillus DDS-l, Lactobacillus fermentum, Lactobacillus gaserii, Lactobacillus GG, Lactobacillus jensenii, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus sporogenes, Lactobacillus thermophilus, and the like.
  • a preferred member of the Sporolactobacillus genus include Sporolactobacillus P44.
  • Degradation of waste products or sanitary products can be readily assessed by any of a variety of processes, and therefore the term "degradation-enhancing" is not to be construed as so limited to any particular degree or rate of enhancement of degradation.
  • the above bacteria are well known in the bacterial arts, and can be obtained from well known sources and propagated by well known methods.
  • An exemplary source is the American Type Culture Collection (ATCC), although other culture banks are also available.
  • ATCC American Type Culture Collection
  • the culturing of bacteria is also well known, and particularly the preparation of spores for the sporulating varieties of bacteria, which are particularly preferred.
  • Bifidogenic Oligosaccharides are a class of sugars particularly useful for preferentially promoting the growth of a lactic acid bacteria of this invention. These oligosaccharides include fructo-oligosaccharides (FOS), gluco- oligosaccharides (GOS), other long-chain oligosaccharide polymers of fructose and/or glucose, and the trisaccharide raffinose, all of which are not readily digested by pathogenic bacteria. The preferential growth is promoted due to the nutrient requirements of this class of lactic acid bacterium as compared to pathogenic bacteria.
  • FOS fructo-oligosaccharides
  • GOS gluco- oligosaccharides
  • Other long-chain oligosaccharide polymers of fructose and/or glucose and the trisaccharide raffinose, all of which are not readily digested by pathogenic bacteria.
  • the preferential growth is promoted due to the nutrient requirements of
  • Bifidogenic oligosaccharides are polymers that are utilized almost exclusively by the indigenous Bifidobacteria and Lactobacillus and can be similarly utilized by Bacillus. Deleterious microorganisms such as Clostridium, Candida, Campylobacter, Klebsiella, Pseudomonas, Staphylococcus, Salmonella and E. coli cannot metabolize FOS or other bifidogenic oligosaccharides, and therefor use of these bifidogenic oligosaccharides in combination with a lactic acid bacteria of this invention, particularly Bacillus, allows the beneficial and probiotic bacteria to grow and to replace any undesirable or pathogenic microorganisms.
  • bifidogenic oligosaccharides in compositions of the present invention provides a synergistic effect thereby increasing the effectiveness of the probiotic-containing compositions of this invention.
  • This synergy is manifest at least by selectively increasing the ability of the probiotic bacterium to grow by increasing the food supplement for probiotic bacteria which preferentially selects for growth of the probiotic bacteria over many other bacterial species in the infected tissue.
  • Bifidobacteria and Lactobacillus are also producers of lactic acid.
  • Bifidogenic oligosaccharides enable these probiotic organisms to proliferate preferentially over the undesirable bacteria that may be present in the tissue to be treated by the present invention, thereby furthering the probiotic state of the body.
  • the presence of the bifidogenic oligosaccharides in the formulation allows for more effective inhibition of undesirable microbes by increasing the ability of all varieties of beneficial probiotic bacteria to grow and therefore provide benefit.
  • the bifidogenic oligosaccharide can be used either alone or in combination with a lactic acid bacterium in a composition. That is, due to the growth promoting activity of bifidogenic oligosaccharides, the invention also contemplates a composition comprising a bifidogenic oligosaccharide of this invention in a lactic acid bacterium growth-promoting amount. As shown herein, these amounts can vary widely since a probiotic lactic acid bacterium will respond to any metabolic amount of nutrient oligosaccharide, and therefore the invention need not be so limited.
  • a preferred and exemplary bifidogenic oligosaccharide is FOS, although the other sugars can also be utilized, either alone or in combination.
  • FOS can be obtained from a variety of natural sources, including commercial suppliers. As a product isolated from natural sources, the components can vary widely and still provide the beneficial agent, namely FOS.
  • FOS typically has a polymer chain length of from about 4 to 100 sugar units, with the longer lengths being preferred. For example, the degree of purity can vary widely so long as functional FOS is present in the formulation.
  • Preferred FOS formulations contain at least 50% by weight of fructo- oligosaccharides compared to simple (mono or disaccharide) sugars such as glucose, fructose or sucrose, preferably at least 30% fructo-oligosaccharides, more preferably at least 90% and most preferably at least 95% fructo-oligosaccharides.
  • Sugar content and composition can be determined by any of a variety of complex carbohydrate analytical detection methods as is well known.
  • FOS Frutafit IQ from Imperial Suiker Unie (Sugar Land, Texas), NutraFlora from Americal Ingredients, Inc., (Anaheim, CA), Fabrchem, Inc., (Fairfield, CT), and Fruittrimfat Replacers and Sweeteners (Emeryville, CA).
  • Bifidogenic oligosaccharides such as GOS, and other long chain oligosaccharides are also available from commercial vendors.
  • the present invention is directed to the discovery that lactic acid bacteria, particularly Bacillus species, can be used in compositions as a probiotic in combination with sanitary products for inhibiting dermal and epithelial microbial infections associated with the use of sanitary products.
  • the compositions can be formulated in many configurations because the bacterium can be presented as a viable organism (e.g., as a vegetative cell or as a spore depending on the species and form of probiotic organism) and colonize tissues associated with use of a sanitary product.
  • the cells/spores can be presented in a variety of compositions suited for use in a sanitary product.
  • the active ingredients i.e., live bacteria or extracellular components, comprise about 0.1%) to about 50% by weight of the final composition, preferably 1% to 10% by weight in the composition.
  • a typical composition will contain in a one gram dosage formulation a concentration of from 10 3 to 10 14 colony forming units (CFU) of viable acid bacterium (i.e., vegetative cell) or bacterial spore, preferably 10 5 to 10 12 colony forming units/g, whereas in other preferred embodiments the concentrations are 10 9 to 10 13 colony forming units/g; 10 5 to 10 7 colony forming units/g; or 10 8 to 10 9 colony forming units/g.
  • CFU colony forming units
  • a composition for use in a sanitary product according to the present invention can further comprise a degradation-enhancing bacteria as described herein.
  • a preferred amount of this bacteria is an amount sufficient to promote degradation, which can be from about 10 4 to 10 14 CFU of viable bacteria for use per unit of sanitary product, preferably about 10 7 to 10 10 CFU per unit, and more preferably about 10 8 to 10 9 CFU per unit.
  • the actual amount in a composition will vary depending upon the amounts of composition to be dispersed into the absorbent structure or other portions of the sanitary product, and upon routes of dispersal.
  • combinations of bacteria may be utilized to afford optimized formulations depending upon the circumstances.
  • various combinations of species of bacteria may be used, and in varying amounts, so long as the primary objective is to provide a probiotic acid bacteria, and the secondary objective is to provide a degradation- enhancing bacteria.
  • the invention contemplates certain preferred combinations.
  • a mixture of bacterial spores is ideally suited for manufacturing and shelf storage.
  • a preferred embodiment utilizes a dispersion of about one billion CFU of R. coagulans spores mixed with about one billion CFU of degradation enhancing bacterial spores, preferably an equal mix of R. licheniformis, B. subtilis, B. pumilis and R. megaterium.
  • a composition may further include from about 10 milligrams (mg) to one gram of a bifidogenic oligosaccharide, preferably a fructo- oligosaccharide.
  • the composition typically contains a lactic acid bacterium growth-promoting amount of the bifidogenic oligosaccharide, which growth-promoting amount can vary widely and be readily measured by growth assays as described herein.
  • the composition will typically contain 10 mg to 1 gm of bifidogenic oligosaccharide per gram of composition depending on the dosage, route of administration and intended usage.
  • the formulation for a composition of this invention may include other probiotic agents or nutrients for promoting spore germination and/or bacterial growth.
  • a particularly preferred material is a bifidogenic factor which promotes growth of beneficial probiotic bacteria as described herein.
  • compositions may also include known antimicrobial agents, known antiviral agents, known antifungal agents, all of which must be compatible with maintaining viability of the compositions.
  • Bacillus active agent when Bacillus organisms or spores are the active agent.
  • the other agents in the compositions can be either synergists or active agents.
  • the known antimicrobial, antiviral and/or antifungal agents are probiotic agents compatible with Bacillus.
  • the compositions may also include known antioxidants, buffering agents, and other agents such as coloring agents, flavorings, vitamins or minerals. Thickening agents may be added to the compositions such as polyvinylpyrrolidone, polyethylene glycol or carboxymethylcellulose.
  • Chemicals used in the present compositions can be obtained from a variety of commercial sources, including Spectrum Quality Products, Inc (Gardena, CA), Seltzer Chemicals, Inc., (Carlsbad, CA) and Jarchem Industries, Inc., (Newark, NJ).
  • the active agents are combined with a carrier that is physiologically compatible with the dermal or epithelial tissue of a human or animal to which it is administered. That is, the carrier is preferably substantially inactive except for surfactant properties used in making a suspension of the active ingredients.
  • the compositions may include other physiologically active constituents that do not interfere with the efficacy of the active agents in the composition.
  • a formulated composition of this invention may be completed in weight using any of a variety of carriers and/or binders.
  • a preferred carrier is micro-crystalline cellulose (MCC) added in an amount sufficient to complete the one gram dosage total weight.
  • MCC micro-crystalline cellulose
  • Carriers can be solid-based dry materials for formulations in tablet, granule or powdered form, and can be liquid or gel-based materials for formulations in liquid or gel forms, which forms depend, in part, upon the manner of use or the manner of manufacturing a sanitary product.
  • Typical carriers for dry formulations include trehalose, malto-dextrin, rice flour, micro- crystalline cellulose (MCC) magnesium stearate, inositol, FOS, gluco-oligosaccharides (GOS), dextrose, sucrose, and the like carriers.
  • composition is dry and includes evaporated oils that produce a tendency for the composition to cake (adherence of the component spores, salts, powders and oils), it is preferred to include dry fillers which distribute the components and prevent caking.
  • dry fillers include MCC, talc, diatomaceous earth, amorphous silica and the like, typically added in an amount of from about 1 to 95 % by weight.
  • the carrier is preferably a formulation in which, for example, R. coagulans can be suspended for hydration by the user before it is administered to the sanitary product or tissue.
  • suitable liquid or gel-based carriers are well known in the art, such as water and physiological salt solutions, urea, alcohols and glycols such as methanol, ethanol, propanol, butanol, ethylene glycol and propylene glycol, and the like.
  • water-based carriers are about neutral pH.
  • the invention describes an aqueous liquid absorbent composition
  • an aqueous liquid absorbing medium i.e., an "absorbent”
  • a microbe-inhibiting amount of an extracellular product isolated from R. coagulans as described herein
  • he absorbent composition is similar to an absorbent structure described herein for a sanitary product insofar as the composition in the absorbent portion of the sanitary product.
  • the composition is formulated to be added to or dispersed into/onto a sanitary product for use of the product according to the methods described for a sanitary product of the present invention, that is to inhibit microbial growth upon use of the product.
  • the composition containing absorbent and the extracellular product is typically produced by admixing the extracellular product with a pre-selected amount of absorbent, and drying or desiccating the admixture to coat the absorbent medium with the microbe-inhibiting extracellular product.
  • the resulting dry composition can be applied directly onto a conventional sanitary product.
  • the manufacture of a composition comprising the absorbent and the extracellular product involves admixing a microbe-inhibiting amount extracellular product prepared as described herein, typically in the ratio of 0.1 to 1 ml of supernatant per gram of absorbent, and thereafter drying the absorbent medium to form the microbe-inhibiting absorbent composition.
  • the absorbent composition may further contain a degradation-enhancing bacteria as described herein in amounts similar to the amounts used in a sanitary product on a weight and volume basis.
  • the absorbent composition may also contain a bifidogenic oligosaccharide as described herein.
  • a preferred composition according to the present invention is an aqueous liquid absorbent composition that comprises an aqueous liquid absorbing medium and an effective amount of a viable lactic acid-producing bacteria according to the present invention, also referred to as an anti-microbial absorbent composition. This composition is useful for application directly onto a sanitary product and has both the absorbent and microbe inhibiting properties described herein.
  • the lactic acid-producing bacteria can be any of the various bacteria described herein, with lactic acid bacteria preferred, and R. coagulans being particularly preferred.
  • the bacteria is typically provided in the composition in the form of dried cells, a dried cell mass or as spores in powder, and can also be formulated into a liquid, paste, powder, granule or pellet formulation.
  • An absorbent anti-microbial composition typically contains about 10 2 to 10 14 CFU viable probiotic acid bacteria per cubic meter of composition, preferably contain about 10 3 to 10 10 CFU, more preferably contain 10 3 to 10 6 CFU or 10 6 to 10 9 CFU, and in preferred embodiments contain 10 8 to 10 9 CFU per cubic meter of absorbent composition.
  • the aqueous liquid absorbing medium can be any of the materials described for an absorbent structure herein, and need not be limited.
  • the absorbent composition can further comprise a bifidogenic oligosaccharide as described herein for an absorbent product, and typically is present in amounts of about 10 mg to 1 gm of oligosaccharide per cc of composition, and preferably about 100 to 500 mg oligosaccharide per cc of composition.
  • the claimed invention is directed at methods for increasing dermal and mucoidal health and inhibiting microbial infections and microbial growth associated with use of sanitary products.
  • the method comprises the use of a sanitary product comprising a viable non- pathogenic lactic acid bacteria, which bacterial promote dermal probiosis.
  • the use of the sanitary product containing bacteria provides contact between the tissue in which the probiotic effect is targeted and the sanitary product, and thereby contacts the target tissue with an effective amount of the active probiotic ingredients in the composition.
  • the claimed invention describes methods for inhibiting dermal or epithelial infections comprising the steps of contacting the surface of a sanitary product of this invention with the skin or mucous membrane of a mammal and maintaining the contact for a time period sufficient to allow initiation of probiotic activity of the lactic acid bacteria or spores in the sanitary product, thereby inhibiting microbial growth adjacent to or on the skin or mucous membrane contacted by the sanitary product.
  • the surface of the sanitary product used in the present method is present on a flexible article selected from the group consisting of a diaper, pliable material for wiping skin or a mucous membrane, dermal patch, adhesive tape, absorbent pad, clothing, tampon, panty protector, incontinence guard, sanitary napkin or the like product.
  • the method can be practiced to inhibit any of a variety of infections and/or irritations known to arise upon use of a sanitary product, including but not limited to diaper rash, eczema, incontinence, menstruation, fluid discharges from wounds and other dermal/epithelial infections or inflammations caused by opportunistic microbial pathogens that overgrow as a result of the irritated or inflamed skin/epithelial tissue, dermatitis, eczema, skin allergies, and the like due to use of the sanitary product.
  • a sanitary product including but not limited to diaper rash, eczema, incontinence, menstruation, fluid discharges from wounds and other dermal/epithelial infections or inflammations caused by opportunistic microbial pathogens that overgrow as a result of the irritated or inflamed skin/epithelial tissue, dermatitis, eczema, skin allergies, and the like
  • the mammal is a human, although the methods and compositions of the invention can be applied to any mammal which would require the use of a sanitary product where dermal infections/inflammations could be problematic.
  • the non-pathogenic lactic acid bacteria is used according to the present invention by applying a sanitary product to a tissue, which product already contains an effective amount of the bacteria incorporated into portions of the sanitary product.
  • a composition of the bacterial may be applied to the sanitary product prior to use.
  • Administration of a composition of this invention to a sanitary product is preferably made using a gel, suspension, spray, powder or semi-solid formulation containing viable bacteria, bacterial spores and/or probiotic extracellular product, all formulated using "good manufacturing practice” (GMP) methods well known in the art.
  • Administration comprises use of typically 0.001 (i.e., 10,000 CFU) to 10 billion colony forming units (CFU) of viable bacteria or spore applied to a unit of sanitary product, although lesser or greater amounts may also be used.
  • Application is preferably by way of spray-drying a spore/bacteria/extracellular product liquid suspension onto the sanitary product's absorbent structure, preferably onto the region of the sanitary product which directly contacts the dermal/epithelial tissue upon use.
  • the absorbent structure Upon use of the sanitary product, the absorbent structure acquires a body fluid, such as urine, excess fluid of fecal matter, blood, tissue exudate, pus, and the like depending upon the type of sanitary product, whereupon the fluid comes into contact with the lactic acid bacteria present in the sanitary product.
  • the bacteria germinates or is motivated to grow as a result of the contact with the body fluid, and using the electrolytes and substrates present in the body fluid proliferates.
  • the bacterial produces metabolites that are effective in mitigating mycotic growth and other microbial pathogens.
  • the growth of the bacterial feeds on the body fluid waste, and produces enzymes with facilitate degradation of the sanitary product.
  • a bifidogenic oligosaccharide is included in a composition of this invention, such as FOS, there is a synergy provided in the form of a selective food supply, as described herein, resulting in selective growth of acid bacteria over food supply- driven growth of pathogenic bacterial.
  • the method comprises administration of a composition of this invention containing the active ingredients to a human or animal in various dosage regimens as described herein to achieve the nutritional result.
  • the method is typically practiced on any animal where inhibiting microbial infection is desired.
  • a human in the preferred user of a sanitary product or composition according to the present invention although the invention can be practiced on any mammal.
  • the mammal can be any livestock or zoological specimen where such inhibition of parasites/pathogens provides economic and health benefits. Any animal can benefit by the claimed methods, including horses, cows, sheep, goats, pigs, and the like domesticated animals. Other purposes are readily apparent to one skilled in the arts of sanitary products.
  • lactic acid-producing bacteria will promote degradation of used sanitary products, when used either alone or in combination with other bacteria.
  • viable lactic acid bacterial growth will exhibit a beneficial probiotic effect onto the skin or epithelial tissue adjacent to the sanitary product in use by out-competing dermal/epithelial pathogens, and by production of extracellular metabolites that inhibit dermal/epithelial pathogens.
  • the invention contemplates a method for enhancing biodegradation of a sanitary product comprising the step of providing an inoculum of viable non-pathogenic lactic acid-producing bacteria according to this invention into the sanitary product, and contacting the sanitary product to the body tissue for use as prescribed/intended for the sanitary product.
  • the presence of the provided inoculum in the used sanitary product together with the collected body fluids/exudates provides an environment for bacterial growth, which facilitates the breakdown of the various components of the sanitary product, including the waste material containing in the disposed sanitary product and the various components making up the sanitary product, such as cellulose, petroleum hydrocarbon polymers, natural and synthetic fibers and adhesives, and the like materials described herein for constructing a sanitary product.
  • the method comprises the use of a non-pathogenic lactic acid bacteria and comprises the use of one or more additional species of bacteria designed to enhance degradation.
  • additional bacteria are non- pathogenic insofar as they are included in the sanitary product, but are not necessarily probiotic in terms of inhibiting dermal or epithelial microbial infections. Rather, these additional bacteria are included solely for the ability to enhance degradation, and are referred collectively as "degradation-enhancing" bacteria.
  • the invention also contemplates various articles of manufacture which utilize the beneficial aspects of the present invention by combination of a composition with various medical or personal hygiene devices so as to reduce or prevent microbial infections associated with the use of these devices.
  • the invention comprises compositions of a probiotic lactic acid bacteria, preferably a lactic acid bacteria, and more preferably a Bacillus species and/or isolated B. coagulans active agent, applied to a solid surface or impregnated into a solid matrix of any device or article of manufacture that is intended to be in contact with skin or a mucous membrane.
  • the solid surface is a flexible article than can be worn on or wiped on the skin or mucous membrane.
  • the flexible item carrying the acid bacteria when the flexible item carrying the acid bacteria is to be worn on the skin it includes a means for attaching the article to the skin such as, for example, an adhesive layer, interengaging hook and pile (i.e., Velcro ® ) connectors, or other well known means of attachment such as ties, snap closures, elastic, buttons, and the like.
  • a means for attaching the article to the skin such as, for example, an adhesive layer, interengaging hook and pile (i.e., Velcro ® ) connectors, or other well known means of attachment such as ties, snap closures, elastic, buttons, and the like.
  • absorbent products having absorbent structures are well known in the art, and can include diapers, towelettes (e.g., baby wipes or feminine hygiene towelettes), sanitary napkins, tampons, panty protectors, dermal patches, adhesive tape, bandages, wound or sore dressings, absorbent pads, incontinence guards, bed sheets or protectors, saliva absorbent, articles of clothing (e.g., underclothes, sleeping apparel), bath towels, wash cloths, and the like.
  • the claimed invention describes an absorbent product comprising an aqueous liquid absorbent structure and an effective amount of viable non-pathogenic acid bacteria according to said invention.
  • Absorbent structures in sanitary products are typically produced by fluffing cellulosic or other fibrous pulp into a roll, bale or sheet for instance, to form a pulp mat, sometimes admixed with so-called superabsorbent materials in the pulp mat.
  • the superabsorbent materials are typically polymeric formulations capable of absorbing many times their own weight of water of body fluid, and are well known in the art.
  • the pulp mat is typically compressed so as to enhance its fluid- wicking ability and also in order to reduce pulp body bulk, and therewith obtain an article which is as compact as possible to achieve the absorbent properties desired in the particular sanitary product.
  • the absorbent structure may also include other constituents, for example, components which will improve fluid acquisition properties, fluid-wicking properties, fluid retention properties, and the like well known in the art. Other included constituents include components which increase coherent strength (i.e., the ability to withstand deformation during use).
  • the absorbent structure may contain fibrous woven, knitted or non woven materials, occlusive or non-occlusive films or membranes, granules, pellets or aggregates of absorbent material, synthetic polymer fibers, films, membranes and foams (e.g., nylon, polytetrafluoroethylene (PTFE, such as Teflon ® or Gor-Tex ® ), polystyrene, polycarbonate, polyvinylchloride and polysulphone). All of these forms are well known in the art and include, for example, knitted or woven fabrics, non- woven fabrics such as felt and batting, fiber balls of cotton, rayon, cellulose or synthetic fibers, and the like materials.
  • the fibers can be natural fibers, including but not limited to: wool, silk, cotton, cellulosic fiber, and the like natural fibers.
  • Natural polymers based on polysaccharide can also be used, including, but not limited to: modified cellulose and cellulose derivatives (e.g., alkyl-, hydroxyalkyl-, carboxymethylcellulose); gum resins (e.g., guar gum, locust bean gum, tragacanth gum, gum arabic, pectin, etc.); starch and starch derivatives (e.g., corn starch, grain starch, potato starch, amylose, amylopectin, dextrin, dextran, modified starch, hydroxy-ethyl starch, cationic starch, starch graft polymers, and the like polymers).
  • modified cellulose and cellulose derivatives e.g., alkyl-, hydroxyalkyl-, carboxymethylcellulose
  • gum resins e.g., gu
  • the fibers can be synthetic fibers, including, but not limited to: polyester, polyolefin, polyamide, polyvinyl alcohol, polyvinyl acetate, polyvinyl chloride, polyvinyl urea, polyurethane, polyurea, polyacrylonitrile, as well as copolymers of these polymers, and the like synthetic fibers.
  • the absorbent product can be formatted into a multi layer configuration, having an absorbent structure layer, a fluid permeable top layer which allows wicking of fluid but is itself non-wettable due to its structural composition (e.g., synthetic fiber construction), and a fluid- impermeable bottom layer (i.e., back sheet) which prevents absorbed fluid to pass from the absorbent structure layer to the adjacent tissues of the user when contacted by the absorbent product during use.
  • a fluid permeable top layer which allows wicking of fluid but is itself non-wettable due to its structural composition (e.g., synthetic fiber construction)
  • a fluid- impermeable bottom layer i.e., back sheet
  • the absorbent product typically contains about 10 2 to 10 14 CFU of viable probiotic acid bacteria per cubic meter (M ) of absorbent product, and is typically dispersed in the form of cells, dried cell mass or spores, with spores being the particularly preferred format.
  • the product will contain about 10 3 to 10 10 CFU per M 3 of absorbent product, and may have 10 3 to 10 6 CFU per M 3 or 10 6 to 10 9 CFU per M 3 , and preferably will have 10 8 to 10 9 CFU per M 2 of absorbent product, although these amounts can vary depending upon the specific application, product formulation and intended use.
  • the absorbent product may further contain a bifidogenic oligosaccharide dispersed therein as described for a composition according to the present invention, typically in amounts of from about 10 milligrams (mg) to 1 gram per cubic centimeter (cc) of absorbent structure, and preferably about 100 to 500 mg of oligosaccharide per cc of structure.
  • a bifidogenic oligosaccharide dispersed therein typically in amounts of from about 10 milligrams (mg) to 1 gram per cubic centimeter (cc) of absorbent structure, and preferably about 100 to 500 mg of oligosaccharide per cc of structure.
  • the absorbent product may further contain a degradation-enhancing bacteria according to the present invention, as described herein.
  • the degradation-enhancing bacteria is different from the probiotic lactic acid-producing bacteria
  • the degradation enhancing bacteria can be incorporated into the absorbent product is regions of the product designed to keep the bacteria away from the skin or tissues of the mammal during use, and designed for release or access to the waste products.
  • an absorbent product will contain from 10 4 to 10 14 CFU of viable degradation-enhancing bacteria per unit of sanitary product, preferably about from 10 7 to 10 10 CFU per unit, and more preferably about from 10 to 10 CFU per unit.
  • a composition containing a lactic acid bacteria of this invention can be applied to any of a variety of regions of an absorbent product of the present invention including the moisture barrier (i.e., the "stay-dry lining"), the absorbent structure (e.g., moisture absorbing polymer), coated onto the external surface that contacts the skin or epithelial tissue, in capsules which are sealed-off until wetted for slow release of bacteria/spores, or combinations thereof.
  • the bacteria can be presented as a spore, a dry or lyophilized cell mass, a stabilized gel or paste, a dry powder, or as a component of the gel polymer that comprises the moisture barrier system.
  • the Bacillus coagulans extracellular product i.e., the "isolated agent”
  • the invention contemplates the use of the extracellular product in place of or in combination with a viable acid bacteria in any of the sanitary products described herein.
  • the lactic acid bacteria and/or a R. coagulans-isolated active agent can be applied to the solid surface using any of a variety of known methods including, for example, applying a powder, spray drying the probiotic onto the material or soaking the material in a solution containing the probiotic and then using the wetted material or drying the material before use.
  • Porous material may contain the Bacillus and/or the isolated active agent in the pores or interstices of the solid material.
  • the Bacillus and/or the isolated active agent can be attached by adhesion, such as by attachment to an adhesive layer that is then applied to the skin (e.g., in a bandage or dermal patch).
  • the Bacillus and/or the isolated active agent can be impregnated into the solid material during the manufacturing process of the flexible article (e.g., added to a synthetic composition before or during the polymerization process).
  • the pressure and heat resistance of Bacillus spores makes them particularly suitable for incorporation into the material during manufacturing.
  • any of the solid materials carrying Bacillus and/or the isolated active agent can be packaged individually or in groups, suitable for holding the treated material using standard packaging materials (e.g., in a shrink wrapper, sealed packet, protective wrapper or dispensing container suitable for holding dry or wet materials)
  • the article of manufacture can have applied thereon any of the additional/optional components of a composition of this invention, including carriers, disinfectants, antibacterial agents, salts, FOS, and the like.
  • the absorbent product can include as a component part of the absorbent structure inert ingredients, neutral filling agents ,and the like.
  • Exemplary neutral filling agents include peat, sand, clay, garden mold, ground shells of nuts or pomaceous fruit, wood flour, chitin-containing flour, and the like well known materials.
  • any of a variety of methods for placing the composition onto a subject article can be used, and therefor the invention need not be so limited.
  • preferred methods include a "spray-dry" method in which the material is exposed in a low humidity chamber to an atomized mix containing a liquid composition, where the chamber is subsequently exposed to about 80-110°F to dry the liquid, thereby impregnating the material of the article with the components of the composition.
  • a typical load is from 10 5 to 10 9 CFU of bacteria/spores per ml of atomizing mix, to place that same amount on about one square inch of external surface of fibrous carrier/article material.
  • the dry article is then ready for storage in a sterile package for use.
  • the invention contemplates the use of viable probiotic acid bacteria in absorbent structures which structures are incorporated into an absorbent product as described herein.
  • the invention describes the use of an effective amount of probiotic lactic acid bacteria where the bacteria is dispersed or incorporated in the form of dried cells or cell mass or as spores into the absorbent structure of an absorbent product according to the invention.
  • the claimed invention further contemplates a system for inhibiting dermal or epithelial infection associated with use of a sanitary product comprising a container comprising label and an absorbent composition according to the present invention, wherein said label comprises instructions for application of the absorbent composition for inhibiting microbial infections during use of the sanitary product.
  • the system is present in the form of a package containing a composition or absorbent product of this invention, or in combination with packaging material.
  • the packaging material includes a label or instructions for use of the components of the package.
  • the instructions indicate the contemplated use of the package component as described herein for the methods or compositions of the invention.
  • a system can comprise one or more unit dosages of a composition according to the invention.
  • the system can contain bulk quantities of a composition.
  • the label contains instructions for using the composition or absorbent product as appropriate, and may include information regarding storage of the composition or absorbent product, application methods, health indications, methods for disposal, and the like information.
  • all scientific and technical terms used herein have the same meaning as commonly understood by those skilled in the relevant art.
  • the techniques employed or contemplated herein are standard methodologies well known to one of ordinary skill in the art. The Examples of embodiments are for illustration only.
  • Example 1 Preparation of Bacillus coagulans Cultures Bacillus coagulans Hammer bacteria (ATCC Accession No. 31284) was inoculated and grown to a cell density of about 10 8 to 10 9 cells/ml in nutrient broth containing 5 g Peptone, 3 g Meat extract, 10-30 mg MnSO 4 , and 1,000 ml distilled water, adjusted to pH 7.0, using a standard airlift fermentation vessel at 30°C. The range of MnSO 4 acceptable for sporulation is 1 mg/1 to 1 g/1. The vegetative cells can actively reproduce up to 45°C, and the spores are stable up to 90°C. After fermentation, the R.
  • coagulans bacterial cells or spores are collected using standard methods (e.g., filtration, centrifugation) and the collected cells and spores can be lyophilized, spray dried, air dried or frozen. As described herein, the supernatant from the cell culture can be collected and used as an extracellular agent secreted by R. coagulans which has antimicrobial activity useful in a formulation of this invention.
  • a typical yield from the above culture is in the range of about 10 9 to 10 10 viable spores and more typically about 100 to 150 billion cells/spores per gram before drying. Spores maintain at least 90% viability after drying when stored at room temperature for up to ten years, and thus the effective shelf life of a composition containing R. coagulans Hammer spores at room temperature is about 10 years.
  • a culture of dried R. coagulans spores was alternately prepared as follows. Ten million spores were inoculated into a one liter culture containing 24 g potato dextrose broth, 10 g of enzymic-digest of poultry and fish tissue, 5 g of FOS and 10 g MnSO4. The culture was maintained for 72 hours under a high oxygen environment at 37°C to produce culture having about 150 billion cells per gram of culture. Thereafter, the culture was filtered to remove culture medium liquid, and the bacterial pellet was resuspended in water and freeze-dried. The freeze- dried powder is then ground to a fine powder using standard good manufacturing practice (GMP).
  • GMP standard good manufacturing practice
  • a one liter culture of R. coagulans was prepared as described in Example 1. The culture was maintained for 5 days as described, at which time FOS was added at 5 g/liter, and the culture was continued. 20 ml of carrot pulp was then added at day 7, and the culture was harvested when the culture became saturated (t.e., no substantial cell division). The culture was first autoclaved for 30 minutes at 250°F, and then centrifuged at 4000 rpm for 15 mm. The resulting supernatant was collected and filtered in a Buchner funnel through a 0.8 micron ( ⁇ m) filter, and the filtrate (i.e., the "pass-through”) was collected and further filtered through a 0.2 ⁇ m Nalge vacuum filter.
  • the resulting pass-through was collected (about 900 ml) to form a liquid containing an extracellular product, and used in inhibition studies.
  • 1 ml of the above-produced extracellular product was added to the test plate in place of live R. coagulans.
  • a zone of inhibition of about 10 to 25 millimeters was observed, indicating a potent antimicrobial activity of "excellent" quality, using the terminology set forth in Example 5.
  • Formulation 1 (Powder for Application to Sanitary Product-) R. coagulans 250,000,000 spores (approximately 17.5 mg)
  • Fructo-oligosaccharides 100 mg
  • MCC Micro-crystalline cellulose
  • Formulation 2 (Diaper-Sanitary Product) Lined diaper containing a composition of:
  • Fructo-oligosaccharides 500 mg
  • MCC Micro-crystalline cellulose
  • Fructo-oligosaccharides 500 mg
  • MCC Micro-crystalline cellulose 1 g dispersed uniformly in the absorbent fibers of the diaper.
  • the ability of R. coagulans to inhibit bacterial pathogens was demonstrated using an in vitro assay.
  • the assay is part of a standard bacterial pathogen screen (U.S. Food and Drug Administration) and is commercially available on solid support disks (DIFCO ® BACTROL ® disk set).
  • DIFCO ® BACTROL ® disk set solid support disks
  • potato-dextrose plates (DIFCO ® ) were prepared using standard procedures and were inoculated individually with a confluent bed 1.5 x 10 6 of each species of bacteria tested.
  • Inhibition by R. coagulans was tested by placing on the plate about 1.5 x 10 6 CFU in 10 ⁇ l of broth or buffer, plated directly in the center of the potato-dextrose plate with one test locus of about 8 mm in diameter per plate.
  • test loci were used for each assay.
  • the negative control was comprised of a 10 ⁇ l drop of a sterile saline solution, whereas the positive control was comprised of a 10 ⁇ l volume of glutaraldehyde.
  • the plates were then incubated for about 18 hr at 30°C when the zone of inhibition was measured.
  • excellent inhibition means the zone was 10 mm or greater in diameter; and “good inhibition” means the zone was greater than 2 mm in diameter, but less than 10 mm in diameter. No inhibition was seen with the negative control and excellent inhibition (about 16.2 mm diameter, average of three tests) was seen with the positive control.
  • excellent inhibition For the enteric organisms tested, Clostridium species and E. coli, excellent inhibition by R. coagulans was seen.
  • the zone of inhibition was consistently greater than 15 mm in diameter.
  • excellent inhibition was also seen for the opportunistic pathogens Pseudomonas aeruginosa, Staphylococcus aureus, and Candida species.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

L'invention concerne des compositions et des procédés visant à inhiber des infections microbiennes associées à l'utilisation de produits hygiéniques tels que couches, pansements, serviettes hygiéniques, tampons et analogue. L'invention concerne l'utilisation d'un produit hygiénique contenant une quantité efficace de bactéries productrices d'acide lactique viables, non pathogènes, telles que Bacillus coagulans ou un produit extracellulaire de celle-ci, utiles pour inhiber la croissance de parasites et de pathogènes sur le tissu épithélial en contact avec le produit hygiénique pendant son utilisation. L'invention prévoit aussi l'amélioration de la biodégradation de produits hygiéniques après utilisation et élimination. L'invention concerne également des procédés d'utilisation du produit ainsi que des dispositifs contenant ces compositions.
PCT/US2000/010222 1999-04-14 2000-04-14 Procedes visant a inhiber des infections microbiennes associees a des produits hygieniques WO2000061201A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002368509A CA2368509A1 (fr) 1999-04-14 2000-04-14 Procedes visant a inhiber des infections microbiennes associees a des produits hygieniques
JP2000610532A JP2002540900A (ja) 1999-04-14 2000-04-14 衛生製品に関連する微生物感染の阻害方法
EP00923406A EP1173233A1 (fr) 1999-04-14 2000-04-14 Procedes visant a inhiber des infections microbiennes associees a des produits hygieniques
AU43533/00A AU780367B2 (en) 1999-04-14 2000-04-14 Methods for inhibiting microbial infections associated with sanitary products

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/291,789 US6716435B1 (en) 1997-04-18 1999-04-14 Absorbent product containing absorbent structure and Bacillus coagulans
US09/291,789 1999-04-14

Publications (1)

Publication Number Publication Date
WO2000061201A1 true WO2000061201A1 (fr) 2000-10-19

Family

ID=23121835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/010222 WO2000061201A1 (fr) 1999-04-14 2000-04-14 Procedes visant a inhiber des infections microbiennes associees a des produits hygieniques

Country Status (5)

Country Link
EP (1) EP1173233A1 (fr)
JP (1) JP2002540900A (fr)
AU (1) AU780367B2 (fr)
CA (1) CA2368509A1 (fr)
WO (1) WO2000061201A1 (fr)

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034168A1 (fr) * 1999-11-08 2001-05-17 Ganeden Biotech, Inc. Inhibitions d'agents pathogènes à l'aide de bactéries probiotiques
WO2001013927A3 (fr) * 1999-08-26 2001-08-30 Ganeden Biotech Inc Compositions topiques ameliorees contenant des bacteries probiotiques, des spores et des produits extra-cellulaires et leur utilisation
EP1197231A1 (fr) * 2000-10-11 2002-04-17 Uni-Charm Corporation Article absorbent pour le contrôle de la flore normal de la peau
WO2002051458A3 (fr) * 2000-10-20 2003-01-16 Miller Brewing Couches-culottes et lingettes humides antimicrobiennes
US6849256B1 (en) 1999-11-08 2005-02-01 Ganeden Biotech Incorporated Inhibition of pathogens by probiotic bacteria
WO2005110504A1 (fr) * 2004-04-30 2005-11-24 Kimberly-Clark Worldwide, Inc. Produits de soins personnels et methode pour inhiber l'adherence de flore bacterienne sur la peau
WO2008060199A1 (fr) * 2006-11-17 2008-05-22 Sca Hygiene Products Ab Ouate cellulosique hygiénique contenant une composition anti-microbienne
WO2008060200A1 (fr) * 2006-11-17 2008-05-22 Sca Hygiene Products Ab Article d'hygiène contenant une composition anti-microbienne
EP1932892A1 (fr) 2006-12-13 2008-06-18 Scapa France Bande à faisceau de bobine
WO2008074331A1 (fr) * 2006-12-19 2008-06-26 Ferrosan A/S Pansement comprenant des bactéries d'acide lactique
WO2009099562A3 (fr) * 2008-01-30 2010-07-29 Ganeden Biotech, Inc. Compositions et procédés pour nettoyer des surfaces
US7785581B2 (en) 2006-06-26 2010-08-31 Qingdao East Sea Pharmaceuticals Ltd. Composition and method for reducing feces toxins and treating digestive disorders
WO2011000123A1 (fr) * 2009-07-01 2011-01-06 Universidad De Concepcion Patchs hydrocolloïdes renfermant des souches viables probiotiques de lactobacillus spp. et utilisés pour le traitement de blessures de diverses natures, dans des tissus infectés, des plaies sèches et des plaies profondes
US7960604B2 (en) 2000-10-03 2011-06-14 Ellen Ab Process for production of an absorbing sanitary article comprising lactic acid producing bacteria
US8092793B2 (en) 2004-12-15 2012-01-10 Qingdao East Sea Pharmaceuticals, Ltd. Treating inflammatory bowel disease with live bacteria
GB2484511A (en) * 2010-10-13 2012-04-18 Sca Hygiene Prod Ab Article comprising a micro-organism capable of cleaving carbon-carbon bonds
EP2155272A4 (fr) * 2007-06-21 2012-06-27 Sca Hygiene Prod Ab Article hygiénique comprenant des lactobacilli dans un support hydrophile
US8222020B2 (en) 2006-11-17 2012-07-17 Sca Hygiene Products Ab Biologically pure strain of Lactobacillus fermentum, strain Ess-1
GB2492171A (en) * 2011-06-24 2012-12-26 Sca Hygiene Prod Ab Sanitary articles comprising biodegradable plastic and Bacillus spores
EP2596776A1 (fr) 2011-11-25 2013-05-29 Micuri ApS Composition probiotique emballée et utilisations associées
WO2014096641A1 (fr) 2012-12-17 2014-06-26 Laboratoires Urgo Méthode pour prévenir et/ou traiter les infections, colonisations ou maladies liées à staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis, bacteroides fragilis, staphylococcus epidermidis, propionibacterium acnes, candida albicans et/ou malassezia furfur
US8821854B2 (en) 1997-04-18 2014-09-02 Ganeden Biotech, Inc. Methods for inhibiting microbial infections associated with sanitary products and for enhancing sanitary product degradation
WO2015100405A1 (fr) 2013-12-24 2015-07-02 Muhammed Majeed Procédé de production de produits métabolites extracellulaires partiellement purifiés à partir de bacillus coagulans, et leurs applications biologiques
WO2015112374A1 (fr) 2014-01-24 2015-07-30 The Procter & Gamble Company Article d'hygiène contenant un micro-organisme
US9193940B2 (en) 2006-08-11 2015-11-24 Novozymes Biologicals, Inc. Bacteria cultures and compositions comprising bacteria cultures
US9228284B2 (en) 2011-02-15 2016-01-05 Novozymes North America, Inc. Mitigation of odor in cleaning machines and cleaning processes
US9265858B2 (en) 2012-06-12 2016-02-23 Ferrosan Medical Devices A/S Dry haemostatic composition
US9446111B2 (en) 2009-04-29 2016-09-20 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
WO2016200716A1 (fr) 2015-06-07 2016-12-15 The Procter & Gamble Company Article de commerce contenant un article absorbant
WO2016205394A1 (fr) * 2015-06-15 2016-12-22 Amnat Global Llc Mélanges probiotiques multi-souches pour le traitement de troubles gastro-intestinaux et l'amélioration ou l'entretien de la santé gastro-intestinale
US9533069B2 (en) 2008-02-29 2017-01-03 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
WO2017014929A1 (fr) 2015-07-23 2017-01-26 The Procter & Gamble Company Patch contenant un microorganisme
US9724078B2 (en) 2013-06-21 2017-08-08 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
WO2018021874A1 (fr) * 2016-07-29 2018-02-01 바이오제닉스코리아 주식회사 Serviette hygiénique fonctionnelle
US10111916B2 (en) 2003-12-05 2018-10-30 Ganeden Biotech, Inc. Compositions comprising Bacillus coagulans spores and whey
US10111980B2 (en) 2013-12-11 2018-10-30 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
US10653837B2 (en) 2014-12-24 2020-05-19 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
CN111304780A (zh) * 2020-03-09 2020-06-19 江苏德邦卫生用品有限公司 一种用于婴儿尿不湿的可降解高吸水性复合材料的制备及应用
US10918796B2 (en) 2015-07-03 2021-02-16 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
US11046818B2 (en) 2014-10-13 2021-06-29 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
US11109849B2 (en) 2012-03-06 2021-09-07 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
CN115354002A (zh) * 2022-09-20 2022-11-18 微康益生菌(苏州)股份有限公司 一种凝结芽孢杆菌bc07、其用途及其抑菌剂、药物、食品和抑菌方法
US11801324B2 (en) 2018-05-09 2023-10-31 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE526982C2 (sv) * 2003-05-27 2005-11-29 Sca Hygiene Prod Ab Enskiktspolymermatrisfilm innefattande mjölksyraproducerande bakterier, framställning samt användning därav
JP2005200316A (ja) * 2004-01-13 2005-07-28 Tooyoo Gijutsu Kenkyusho:Kk ハスの破砕物および／または抽出物を含む動物用飼料、動物用飼料添加剤並びに動物用薬剤
JP6316061B2 (ja) * 2014-03-28 2018-04-25 ユニ・チャーム株式会社 吸収性物品
CN111093622A (zh) * 2017-06-06 2020-05-01 萨米莱布斯有限公司 来自凝结芽孢杆菌的胞外代谢物的皮肤护理应用
WO2021182377A1 (fr) * 2020-03-13 2021-09-16 ニュートリー株式会社 Inhibiteur de croissance de clostridiodes difficile
JP2024168547A (ja) * 2023-05-24 2024-12-05 ユニ・チャーム株式会社 吸収性物品及び包装体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000077A1 (fr) * 1989-06-26 1991-01-10 Micro Vesicular Systems, Inc. Dispositif biodegradable d'incontinence
WO1992013577A1 (fr) * 1991-02-05 1992-08-20 Lecur Development In Sweden Aktiebolag Tampon ou serviette sanitaire comportant des bacteries produisant de l'acide lactique
GB2303305A (en) * 1995-07-13 1997-02-19 Moelnlycke Ab Inhibiting the growth of micro-organisms in absorbent articles
DE19713908A1 (de) * 1997-04-04 1998-10-08 Symbio Herborn Group Gmbh & Co Vaginaltampon und Verfahren zu seiner Herstellung
WO1998047374A1 (fr) * 1997-04-18 1998-10-29 Ganeden Biotech, Inc. Utilisation topique de spores de bacilles probiotiques pour prevenir ou traiter les infections microbiennes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000077A1 (fr) * 1989-06-26 1991-01-10 Micro Vesicular Systems, Inc. Dispositif biodegradable d'incontinence
WO1992013577A1 (fr) * 1991-02-05 1992-08-20 Lecur Development In Sweden Aktiebolag Tampon ou serviette sanitaire comportant des bacteries produisant de l'acide lactique
GB2303305A (en) * 1995-07-13 1997-02-19 Moelnlycke Ab Inhibiting the growth of micro-organisms in absorbent articles
DE19713908A1 (de) * 1997-04-04 1998-10-08 Symbio Herborn Group Gmbh & Co Vaginaltampon und Verfahren zu seiner Herstellung
WO1998047374A1 (fr) * 1997-04-18 1998-10-29 Ganeden Biotech, Inc. Utilisation topique de spores de bacilles probiotiques pour prevenir ou traiter les infections microbiennes

Cited By (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544363B2 (en) 1997-04-18 2009-06-09 Ganeden Biotech, Inc. Topical compositions containing Bacillus coagulans extracellular products and uses thereof
US7807185B2 (en) 1997-04-18 2010-10-05 Ganeden Biotech, Incorporated Methods of inhibiting growth of bacteria, yeast, fungus, and virus with Pseudomonas lindbergii and Bacillus coagulans extracellular products
US6645506B1 (en) 1997-04-18 2003-11-11 Ganeden Biotech, Inc. Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil
US7541042B2 (en) 1997-04-18 2009-06-02 Ganeden Biotech, Inc. Topical compositions containing Bacillus coagulans extracellular products and uses thereof
US6723326B1 (en) 1997-04-18 2004-04-20 Ganeden Biotech, Inc. Topical compositions containing probiotic Bacillus bacteria, spores, and extracellular products and uses thereof
US8821854B2 (en) 1997-04-18 2014-09-02 Ganeden Biotech, Inc. Methods for inhibiting microbial infections associated with sanitary products and for enhancing sanitary product degradation
US6905692B2 (en) 1997-04-18 2005-06-14 Ganeden Biotech, Inc. Topical compositions containing probiotic bacillus bacteria, spores, and extracellular products and uses thereof
EP1632239A1 (fr) * 1999-08-26 2006-03-08 Ganeden Biotech, Inc. Composition pharmaceutique comprenant du surnageant de Pseudomonas lindbergii et du surnageant de Bacillus coagulans ainsi que son utilisation
WO2001013927A3 (fr) * 1999-08-26 2001-08-30 Ganeden Biotech Inc Compositions topiques ameliorees contenant des bacteries probiotiques, des spores et des produits extra-cellulaires et leur utilisation
US8277799B2 (en) 1999-11-08 2012-10-02 Ganeden Biotech, Incorporated Inhibition of pathogens by probiotic bacteria
US6849256B1 (en) 1999-11-08 2005-02-01 Ganeden Biotech Incorporated Inhibition of pathogens by probiotic bacteria
WO2001034168A1 (fr) * 1999-11-08 2001-05-17 Ganeden Biotech, Inc. Inhibitions d'agents pathogènes à l'aide de bactéries probiotiques
US7713726B2 (en) 1999-11-08 2010-05-11 Ganeden Biotech Incorporated Inhibition of pathogens by probiotic bacteria
US7960604B2 (en) 2000-10-03 2011-06-14 Ellen Ab Process for production of an absorbing sanitary article comprising lactic acid producing bacteria
KR100808891B1 (ko) 2000-10-11 2008-03-03 유니챰 가부시키가이샤 피부 상주균을 조절하는 흡수성 물품
US6706941B2 (en) 2000-10-11 2004-03-16 Uni-Charm Corporation Absorbent article for controlling normal flora of the skin
EP1197231A1 (fr) * 2000-10-11 2002-04-17 Uni-Charm Corporation Article absorbent pour le contrôle de la flore normal de la peau
US7105177B1 (en) 2000-10-20 2006-09-12 Miller Brewing Company Antimicrobial diapers and wet wipes
WO2002051458A3 (fr) * 2000-10-20 2003-01-16 Miller Brewing Couches-culottes et lingettes humides antimicrobiennes
US10111916B2 (en) 2003-12-05 2018-10-30 Ganeden Biotech, Inc. Compositions comprising Bacillus coagulans spores and whey
GB2430157A (en) * 2004-04-30 2007-03-21 Kimberly Clark Co Personal care products and methods for inhibiting the adherence of flora to skin
WO2005110504A1 (fr) * 2004-04-30 2005-11-24 Kimberly-Clark Worldwide, Inc. Produits de soins personnels et methode pour inhiber l'adherence de flore bacterienne sur la peau
GB2430157B (en) * 2004-04-30 2009-02-11 Kimberly Clark Co Personal care products and methods for inhibiting the adherence of flora to skin
US8110215B2 (en) 2004-04-30 2012-02-07 Kimberly-Clark Worldwide, Inc. Personal care products and methods for inhibiting the adherence of flora to skin
US8092793B2 (en) 2004-12-15 2012-01-10 Qingdao East Sea Pharmaceuticals, Ltd. Treating inflammatory bowel disease with live bacteria
US7785581B2 (en) 2006-06-26 2010-08-31 Qingdao East Sea Pharmaceuticals Ltd. Composition and method for reducing feces toxins and treating digestive disorders
US9193940B2 (en) 2006-08-11 2015-11-24 Novozymes Biologicals, Inc. Bacteria cultures and compositions comprising bacteria cultures
AU2006350772B2 (en) * 2006-11-17 2013-01-24 Essity Hygiene And Health Aktiebolag Hygiene tissue comprising a microbe-inhibiting composition
WO2008060199A1 (fr) * 2006-11-17 2008-05-22 Sca Hygiene Products Ab Ouate cellulosique hygiénique contenant une composition anti-microbienne
US9283297B2 (en) 2006-11-17 2016-03-15 Sca Hygiene Products Ab Sanitary article comprising a microbe-inhibiting composition
EP2081607A4 (fr) * 2006-11-17 2012-04-04 Sca Hygiene Prod Ab Ouate cellulosique hygiénique contenant une composition anti-microbienne
EP2081606A4 (fr) * 2006-11-17 2012-04-11 Sca Hygiene Prod Ab Article d'hygiène contenant une composition anti-microbienne
CN109010900A (zh) * 2006-11-17 2018-12-18 Sca卫生用品公司 包含微生物抑制性组合物的卫生织物
US9125768B2 (en) 2006-11-17 2015-09-08 Sca Hygiene Products Ab Hygiene tissue comprising a microbe-inhibiting composition
US8222020B2 (en) 2006-11-17 2012-07-17 Sca Hygiene Products Ab Biologically pure strain of Lactobacillus fermentum, strain Ess-1
WO2008060200A1 (fr) * 2006-11-17 2008-05-22 Sca Hygiene Products Ab Article d'hygiène contenant une composition anti-microbienne
AU2006350772C1 (en) * 2006-11-17 2013-05-23 Essity Hygiene And Health Aktiebolag Hygiene tissue comprising a microbe-inhibiting composition
EP1932892A1 (fr) 2006-12-13 2008-06-18 Scapa France Bande à faisceau de bobine
WO2008071595A1 (fr) * 2006-12-13 2008-06-19 Scapa France Ruban de harnais à fils
WO2008074331A1 (fr) * 2006-12-19 2008-06-26 Ferrosan A/S Pansement comprenant des bactéries d'acide lactique
EP2155272A4 (fr) * 2007-06-21 2012-06-27 Sca Hygiene Prod Ab Article hygiénique comprenant des lactobacilli dans un support hydrophile
WO2009099562A3 (fr) * 2008-01-30 2010-07-29 Ganeden Biotech, Inc. Compositions et procédés pour nettoyer des surfaces
US9533069B2 (en) 2008-02-29 2017-01-03 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
US9757442B2 (en) 2009-04-29 2017-09-12 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
US9446111B2 (en) 2009-04-29 2016-09-20 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
WO2011000123A1 (fr) * 2009-07-01 2011-01-06 Universidad De Concepcion Patchs hydrocolloïdes renfermant des souches viables probiotiques de lactobacillus spp. et utilisés pour le traitement de blessures de diverses natures, dans des tissus infectés, des plaies sèches et des plaies profondes
GB2484511A (en) * 2010-10-13 2012-04-18 Sca Hygiene Prod Ab Article comprising a micro-organism capable of cleaving carbon-carbon bonds
US10577738B2 (en) 2011-02-15 2020-03-03 Novozymes Biologicals, Inc. Mitigation of odor in cleaning machines and cleaning processes
US9228284B2 (en) 2011-02-15 2016-01-05 Novozymes North America, Inc. Mitigation of odor in cleaning machines and cleaning processes
US10968556B2 (en) 2011-02-15 2021-04-06 Novozymes Biologicals, Inc. Mitigation of odor in cleaning machines and cleaning processes
US9404208B2 (en) 2011-02-15 2016-08-02 Novozymes Biologicals, Inc. Mitigation of odor in cleaning machines and cleaning processes
US9982382B2 (en) 2011-02-15 2018-05-29 Novozymes Biologicals, Inc. Mitigation of odor in cleaning machines and cleaning processes
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
US11351206B2 (en) 2011-03-31 2022-06-07 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
GB2492171A (en) * 2011-06-24 2012-12-26 Sca Hygiene Prod Ab Sanitary articles comprising biodegradable plastic and Bacillus spores
WO2013076272A1 (fr) 2011-11-25 2013-05-30 Micuri Aps Composition probiotique emballée et ses utilisations
EP2596776A1 (fr) 2011-11-25 2013-05-29 Micuri ApS Composition probiotique emballée et utilisations associées
US11109849B2 (en) 2012-03-06 2021-09-07 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
US9999703B2 (en) 2012-06-12 2018-06-19 Ferrosan Medical Devices A/S Dry haemostatic composition
US10799611B2 (en) 2012-06-12 2020-10-13 Ferrosan Medical Devices A/S Dry haemostatic composition
US9265858B2 (en) 2012-06-12 2016-02-23 Ferrosan Medical Devices A/S Dry haemostatic composition
WO2014096641A1 (fr) 2012-12-17 2014-06-26 Laboratoires Urgo Méthode pour prévenir et/ou traiter les infections, colonisations ou maladies liées à staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis, bacteroides fragilis, staphylococcus epidermidis, propionibacterium acnes, candida albicans et/ou malassezia furfur
US10595837B2 (en) 2013-06-21 2020-03-24 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
US9724078B2 (en) 2013-06-21 2017-08-08 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
US11103616B2 (en) 2013-12-11 2021-08-31 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
US10111980B2 (en) 2013-12-11 2018-10-30 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
WO2015100405A1 (fr) 2013-12-24 2015-07-02 Muhammed Majeed Procédé de production de produits métabolites extracellulaires partiellement purifiés à partir de bacillus coagulans, et leurs applications biologiques
EP2989197A4 (fr) * 2013-12-24 2016-04-06 Majeed Muhammed Procédé de production de produits métabolites extracellulaires partiellement purifiés à partir de bacillus coagulans, et leurs applications biologiques
WO2015112374A1 (fr) 2014-01-24 2015-07-30 The Procter & Gamble Company Article d'hygiène contenant un micro-organisme
US11046818B2 (en) 2014-10-13 2021-06-29 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
US10653837B2 (en) 2014-12-24 2020-05-19 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
WO2016200716A1 (fr) 2015-06-07 2016-12-15 The Procter & Gamble Company Article de commerce contenant un article absorbant
WO2016205394A1 (fr) * 2015-06-15 2016-12-22 Amnat Global Llc Mélanges probiotiques multi-souches pour le traitement de troubles gastro-intestinaux et l'amélioration ou l'entretien de la santé gastro-intestinale
US10918796B2 (en) 2015-07-03 2021-02-16 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
WO2017014929A1 (fr) 2015-07-23 2017-01-26 The Procter & Gamble Company Patch contenant un microorganisme
KR20180013793A (ko) * 2016-07-29 2018-02-07 바이오제닉스코리아 주식회사 기능성 생리대
WO2018021874A1 (fr) * 2016-07-29 2018-02-01 바이오제닉스코리아 주식회사 Serviette hygiénique fonctionnelle
KR102087051B1 (ko) 2016-07-29 2020-03-10 바이오제닉스코리아 주식회사 기능성 생리대
US11801324B2 (en) 2018-05-09 2023-10-31 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition
CN111304780A (zh) * 2020-03-09 2020-06-19 江苏德邦卫生用品有限公司 一种用于婴儿尿不湿的可降解高吸水性复合材料的制备及应用
CN111304780B (zh) * 2020-03-09 2022-06-21 江苏德邦卫生用品有限公司 一种用于婴儿尿不湿的可降解高吸水性复合材料的制备及应用
CN115354002A (zh) * 2022-09-20 2022-11-18 微康益生菌(苏州)股份有限公司 一种凝结芽孢杆菌bc07、其用途及其抑菌剂、药物、食品和抑菌方法
CN115354002B (zh) * 2022-09-20 2023-12-19 微康益生菌(苏州)股份有限公司 一种凝结芽孢杆菌bc07、其用途及其抑菌剂、药物、食品和抑菌方法

Also Published As

Publication number Publication date
CA2368509A1 (fr) 2000-10-19
AU780367B2 (en) 2005-03-17
EP1173233A1 (fr) 2002-01-23
AU4353300A (en) 2000-11-14
JP2002540900A (ja) 2002-12-03

Similar Documents

Publication Publication Date Title
AU780367B2 (en) Methods for inhibiting microbial infections associated with sanitary products
US8821854B2 (en) Methods for inhibiting microbial infections associated with sanitary products and for enhancing sanitary product degradation
EP2081606B1 (fr) Article d'hygiène contenant une composition anti-microbienne
EP2081607B1 (fr) Ouate cellulosique hygiénique contenant une composition anti-microbienne
JP2002540900A5 (fr)
SK3098A3 (en) Inhibiting the growth of bacteria in absorbent articles by adding other bacteria
SE513261C2 (sv) Absorberande alster innefattande en synergistisk kombination av en pH-reglerande substans och mjölksyrabakterier
CN101678147A (zh) 亲水性载体中含乳酸杆菌的卫生用品
AU2004238175B2 (en) New product
WO2010126414A1 (fr) Procédé pour conserver l'activité de bactéries probiotiques dans des articles de soin personnel et article de soin personnel comprenant les bactéries probiotiques
EP4450042A1 (fr) Supports solides enduits de probiotiques et de métabolites de bactéries probiotiques ou les incorporant
EP4450039A1 (fr) Supports solides enduits de probiotiques et de métabolites de bactéries probiotiques ou les incorporant
AU2023315957A1 (en) Methods and compositions related to prebiotic formulations useful in promoting urogenital health

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2368509

Country of ref document: CA

Ref country code: CA

Ref document number: 2368509

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 610532

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000923406

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000923406

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000923406

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载